Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

111.59 +0.72 (+0.65%)
Streaming Delayed Price Updated: 11:14 AM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
Gilead’s Yeztugo HIV Shot Poised For Wider Reach After SCOTUS Ruling On Preventive Coverage: Wells Fargo
The Supreme Court upheld the Affordable Care Act’s no-cost insurance mandate for preventive care, including HIV PrEP, a move analysts say supports broad access to Gilead’s new drug Yeztugo. 
Via Stocktwits
Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care
Jefferies termed the Supreme Court’s ruling an ‘incremental positive’ for Gilead that removes an overhang going into the launch for Yeztugo. 
Via Stocktwits
Why This Looming Supreme Court Decision Could Rattle Gilead Sciences
The U.S. Supreme Court could make a decision Friday that would rattly Gilead Sciences' newest HIV prevention drug. 
Via Investor's Business Daily
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy
The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in. 
Via Benzinga
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. 
Via Investor's Business Daily
Topics Government
4 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. 
Via Stocktwits
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call
Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the... 
Via StockStory
Topics Earnings Intellectual Property World Trade
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price. 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
GILEAD SCIENCES INC (NASDAQ:GILD) is a quality stock with strong profitability, high ROIC, and reasonable valuation, making it a candidate for long-term investors. 
Via Chartmill
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Analysts at Oppenheimer, BMO, Morgan Stanley, and Mizuho weighed in with positive long-term views, though Oppenheimer flagged near-term headwinds tied to court risks and cannibalization of existing... 
Via Stocktwits
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug
The drug will sell under the brand name Yeztugo. In clinical testing, it kept 99.9% of patients from contracting HIV. 
Via Investor's Business Daily
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising concerns over global access and equity. 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A potential undervalued opportunity in biopharma
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability and reasonable growth, making it a candidate for value investors. The stock trades below industry averages on key valuation... 
Via Chartmill
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Why Gilead Scinces Stock Tumbled on Tuesday
Via The Motley Fool
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes
The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. 
Via Stocktwits
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of... 
Via Stocktwits
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may... 
Via StockStory
Topics Stocks
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035. 
Via Benzinga
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. 
Via Stocktwits
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Gilead Chief Commercial Officer Johanna Mercier told Reuters that the company is eyeing a “global approach" to the launch of Lenacapavir. 
Via Stocktwits
Topics Government
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.